Clinical Trial Update: Study on the Efficacy and Safety of QLM1016 in Schizophrenia [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial evaluating the efficacy and safety of QLM1016 for schizophrenia, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• QLM1016

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: NOT_YET_RECRUITING